HIV感染者腹部内脏脂肪过多的不同表现:两例病例揭示替沙莫林与GLP-1受体激动剂的不同治疗路径
两例HIV-1感染者虽病毒控制良好但出现中心性肥胖,一例BMI 27 kg/m²采用替沙莫林后腰围、血脂及功能状态改善,另一例高BMI女性用GLP-1受体激动剂因用药间断体重波动且腹部脂肪持续,加用替沙莫林后更 targeted 减少内脏脂肪。提示EVAF可独立于BMI存在,治疗应基于脂肪分布而非体重个体化选择。
要点
- EVAF可存在于BMI正常或轻度升高者,体重评估可能漏诊。
- 替沙莫林选择性减少内脏脂肪,GLP-1受体激动剂为非特异性减重。
- 治疗应根据脂肪分布个体化,而非仅依据体重。
核心结论
- HIV感染者中EVAF表现异质,可独立于BMI类别持续存在,并对针对全身肥胖与选择性内脏脂肪的治疗反应不同。
- 支持基于脂肪分布而非单纯体重制定个体化管理策略。
研究设计与样本
- 两例病例报告:两例HIV控制良好的成人出现中心性肥胖。
- 第一例为非肥胖内脏脂肪表型,BMI 27 kg/m²,腰围增加。
- 第二例为BMI更高的女性,代表肥胖表型。
主要发现
- 第一例替沙莫林治疗后腰围显著下降、血脂改善、功能状态提升。
- 第二例GLP-1受体激动剂因用药间断导致体重波动且腹部脂肪持续。
- 第二例加用替沙莫林后对减少内脏脂肪更 targeted。
临床怎么用
- 对HIV感染者应关注中心性肥胖和腰围,即使BMI正常或轻度升高。
- 非肥胖内脏脂肪表型可优先考虑替沙莫林选择性减少内脏脂肪。
- GLP-1受体激动剂适用于全身性肥胖,但需保证用药连续性。
- 高BMI患者GLP-1效果不佳或腹部脂肪持续时,可考虑加用替沙莫林。
局限性
- 仅两例病例报告,结论不能推广至所有HIV感染者。
- 未报告样本量、P值等统计指标或长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI). This pattern of fat accumulation is associated with metabolic dysfunction, cardiovascular risk, and reduced quality of life. Since EVAF can present without generalized obesity, weight-based assessments may fail to identify it; moreover, addressing EVAF warrants distinct approaches based on a patient's presentation. Two therapeutic classes have been studied in this setting: growth hormone-releasing hormone analog (tesamorelin), which selectively reduces visceral fat, and glucagon-like peptide (GLP-1) receptor agonists, which induces generalized weight loss in a nonspecific way. CASE PRESENTATIONS: Two adults with well-controlled HIV presented with central adiposity. The first patient demonstrated a nonobese visceral adiposity phenotype characterized by increased waist circumference (WC) and a BMI of 27 kg/m². Treatment with tesamorelin led to marked reductions in WC, improved lipid levels, and enhanced functional well-being. The second patient, a woman with higher BMI representative of obesity, received a GLP-1; however, her intermittent access to the medication resulted in fluctuating weight trends and persistent abdominal fat. Incorporation of tesamorelin provided a more targeted approach to reduce visceral adiposity in this context. RESULTS: Both cases demonstrated that EVAF may persist independent of BMI category and may respond differently to therapies targeting generalized obesity versus selective visceral abdominal fat. CONCLUSIONS: These cases highlight the heterogeneity of EVAF in PLWH and support individualized management strategies informed by fat distribution rather than weight alone.
引用
- Beach R, Tims-Cook Z, McGary CS, et al. Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. Clin Infect Dis. 2026. PMID: 42139091. doi:10.1093/cid/ciag121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。